Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD

BACKGROUND: We have reported promising outcomes using a staged approach, in which bortezomib/thalidomide/dexamethasone was used only in 14 patients with suboptimal response to VAD (vincristine/adriamycin/dexamethasone) before autologous stem cell transplantation (ASCT). Here we compared the outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chim, Chor Sang, Lie, Albert Kwok Wai, Chan, Eric Yuk Tat, Liu, Herman Sung Yu, Lau, Ching Wa, Yip, Sze Fai, Sim, Joycelyn, Wan, Thomas Shek-Kong, Ma, Edmond Shiu-Kwan, Liang, Raymond, Tse, Eric, Kwong, Yok-Lam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418573/
https://www.ncbi.nlm.nih.gov/pubmed/22682027
http://dx.doi.org/10.1186/1756-8722-5-28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418573/
https://www.ncbi.nlm.nih.gov/pubmed/22682027
http://dx.doi.org/10.1186/1756-8722-5-28

Ejemplares similares